8-K: Microbot Medical CEO to Speak at Robotic Surgery Meeting

Microbot Medical Inc. announced its CEO will present on endovascular robotics at the Society of Robotic Surgery annual meeting.

Summary

• Microbot Medical Inc. announced that its CEO, Harel Gadot, will participate in the Society of Robotic Surgery (SRS) annual meeting from July 23-26, 2026, in Fort Lauderdale, FL.
• Gadot will present an overview of the endovascular robotic market and discuss emerging technologies in peripheral vascular, neurovascular, and cardiovascular spaces.
• The panel session, 'Neurovascular Robotics,' will be livestreamed on Saturday, July 25th, at 10:25 am ET.
• The company highlights the growing importance of endovascular robotics, noting last year was the first time it was featured at SRS.
• Microbot Medical recently received the Innovative Start-Up Award from Surgical Robotics Technology (SRT).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive announcement, highlighting industry engagement and recognition, but lacking specific financial or operational performance data.

Positives

• CEO participation in a prominent industry event (SRS annual meeting) signifies industry recognition.
• Continued focus on endovascular robotics at SRS underscores market growth and Microbot's position.
• FDA clearance of the LIBERTY System less than a year ago.
• Growing adoption of the LIBERTY System at leading academic centers in the U.S.
• Recent win of the Innovative Start-Up Award from Surgical Robotics Technology (SRT).

Risks

• Market conditions.
• Risks inherent in the commercialization of the LIBERTY Endovascular Robotic System.
• Uncertainty in the results of regulatory pathways and regulatory approvals.
• Disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries.
• Maintenance of intellectual property rights.

Future Outlook

The company's participation and presentation at the SRS meeting are intended to highlight the growing importance of endovascular robotics and the company's innovative technologies in peripheral vascular, neurovascular, and cardiovascular spaces.

Management Comments

• The continued focus on this segment of the market underscores its increasing importance within the robotic surgery landscape.
• The Company believes the continued focus on this segment of the market underscores its increasing importance within the robotic surgery landscape.

Industry Context

StockSavvy.ai notes that Microbot Medical's participation in the Society of Robotic Surgery annual meeting, particularly with a focus on endovascular robotics, aligns with the broader trend of increasing automation and technological advancement in surgical procedures across various medical specialties.

Stakeholder Impact

• Shareholders may see increased visibility and potential interest in the company's technology due to industry event participation and awards.
• The medical community and potential customers will be exposed to the LIBERTY Endovascular Robotic System and its applications.

Next Steps

• CEO Harel Gadot to present at the SRS annual meeting.
• Livestream of the 'Neurovascular Robotics' panel session.

Key Dates

Keywords

Robotic Surgery, Endovascular Robotics, Medical Device, Microbot Medical, LIBERTY System, SRS, Neurovascular, Cardiovascular